Multitask Deep Learning Models of Combined Industrial Absorption, Distribution, Metabolism, and Excretion Datasets to Improve Generalization.

Mol Pharm

Drug Metabolism & Pharmacokinetics (DMPK), Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.

Published: March 2025

The optimization of absorption, distribution, metabolism, and excretion (ADME) profiles of compounds is critical to the drug discovery process. As such, machine learning (ML) models for ADME are widely used for prioritizing the design and synthesis of compounds. The effectiveness of ML models for ADME depends on the availability of high-quality experimental data for a diverse set of compounds that is relevant to the emerging chemical space being explored by the drug discovery teams. To that end, ADME data sets from Genentech and Roche were combined to evaluate the impact of expanding the chemical space on the performance of ML models, a first experiment of its kind for large-scale, historical ADME data sets. The combined ADME data set consisted of over 1 million individual measurements distributed across 11 assay end points. We utilized a multitask (MT) neural network architecture that enables the modeling of multiple end points simultaneously and thereby exploits information transfer between interconnected ADME end points. Both single- and cross-site MT models were trained and compared against single-site, single-task baseline models. Given the differences in assay protocols across the two sites, the data for corresponding end points across sites were modeled as separate tasks. Models were evaluated against test sets representing varying degrees of extrapolation difficulty, including cluster-based, temporal, and external test sets. We found that cross-site MT models appeared to provide a greater generalization capacity compared to single-site models. The performance improvement of the cross-site MT models was more pronounced for the relatively "distant" external and temporal test sets, suggesting an expanded applicability domain. The data exchange exercise described here demonstrates the value of expanding the learning from ADME data from multiple sources without the need to aggregate such data when the experimental methods are disparate.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.molpharmaceut.4c01086DOI Listing

Publication Analysis

Top Keywords

adme data
16
cross-site models
12
test sets
12
models
10
learning models
8
absorption distribution
8
distribution metabolism
8
metabolism excretion
8
adme
8
drug discovery
8

Similar Publications

Background: Critically ill children are at risk for subtherapeutic antibiotic concentrations. The frequency of target attainment and risk factors for subtherapeutic concentrations of cefepime in children have not been extensively studied.

Methods: We performed an observational study in critically ill children receiving a new prescription of standard dosing of cefepime for suspected sepsis (≥2 systemic inflammatory response syndrome criteria within 48 hours of cefepime start).

View Article and Find Full Text PDF

Combatting antibiotic resistance in Gardnerella vaginalis: A comparative in silico investigation for drug target identification.

PLoS One

March 2025

Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.

Gardnerella vaginalis is the most frequently identified bacterium in approximately 95% of bacterial vaginosis (BV) cases. This species often exhibits resistance to multiple antibiotics, posing challenges for treatment. Therefore, there is an urgent need to develop and explore alternative therapeutic strategies for managing bacterial vaginosis.

View Article and Find Full Text PDF

Importance: Excess body fat plays a pivotal role in the pathogenesis of heart failure with preserved ejection fraction (HFpEF). HU6 is a novel, controlled metabolic accelerator that enhances mitochondrial uncoupling resulting in increased metabolism and fat-specific weight loss.

Objective: To assess efficacy and safety of HU6 in reducing body weight, improving peak volume of oxygen consumption (VO2) and body composition among patients with obesity-related HFpEF.

View Article and Find Full Text PDF

The development of standard drugs for some unusual cancers, including estrogen-nonresponsive breast cancer, is somewhat difficult within a very short time. So, considering the current situation, phytoestrogen may be a potential candidate for unraveling chemotherapeutics agents. The reason for this review article is to manifest overall information regarding the effects of phytoestrogen on triple-negative breast cancer (TNBC), along with its related cellular and molecular pathways in different TNBC models.

View Article and Find Full Text PDF

Seladelpar for the Treatment of Primary Biliary Cholangitis.

Ann Pharmacother

March 2025

Department of Pharmacy Education and Practice, College of Pharmacy, University of Florida, Gainesville, FL, USA.

Objective: To review the published data including the pharmacology, efficacy, and safety of seladelpar, a peroxisome proliferator-activated receptor delta (PPARδ) agonist leading to the Food and Drug Administration (FDA) accelerated approval for the treatment of primary biliary cholangitis (PBC).

Data Sources: A PubMed (January 1, 1985 to January 27, 2025) literature search was performed using the terms seladelpar, MBX-8025, peroxisome proliferator-activated receptor agonist, and PBC. Other data sources included Google Scholar and the National Institutes of Health Clinical Trials Registry.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!